Institution · Zynerba Pharmaceuticals (United States)

Most cited papers from Zynerba Pharmaceuticals (United States)

Zynerba Pharmaceuticals (United States)

What are the most cited papers from Zynerba Pharmaceuticals (United States)?

The most cited paper from Zynerba Pharmaceuticals (United States) is "Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients" (Nancy A. Haug, Claudia B. Padula, James E. Sottile et al., 2017), with 168 citations. Next come "Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle" (157) and "Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid" (114).

Published TypeFieldAccessCitations

Showing 24 of 24 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients Nancy A. Haug, Claudia B. Padula, James E. Sottile et al. · Addictive Behaviors Open access	9 Mar 2017	168
2	Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle Gustavo González‐Cuevas, Rémi Martin‐Fardon, Tony M. Kerr et al. · Neuropsychopharmacology Open access	22 Mar 2018	157
3	Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid John J. Merrick, Brian Lane, Terri B. Sebree et al. · Cannabis and Cannabinoid Research Open access	8 Apr 2016	114
4	A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome Helen Heussler, Jonathan Cohen, Natalie Silove et al. · Journal of Neurodevelopmental Disorders Open access	2 Aug 2019	106
5	A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX) Elizabeth Berry‐Kravis, Randi Jenssen Hagerman, Dejan B. Budimirovic et al. · Journal of Neurodevelopmental Disorders Open access	25 Nov 2022	67
6	Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism Jerzy Zieba, Duncan Sinclair, Terri B. Sebree et al. · Pharmacology Biochemistry and Behavior Open access	7 May 2019	61
7	Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole R. Tartaglia, Marcel O. Bonn‐Miller, Randi Jenssen Hagerman · Cannabis and Cannabinoid Research Open access	Mar 2019	55
8	Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis David John Hunter, G. Oldfield, Nancy Tich et al. · Osteoarthritis and Cartilage Open access	Apr 2018	50
9	Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies Ingrid Eileen Scheffer, Joe Hulihan, John A. Messenheimer et al. · JAMA Network Open Open access	3 Sep 2021	38
10	A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy Mark S. Wallace, Thomas D. Marcotte, Joseph Hampton Atkinson et al. · Journal of Pain Open access	18 Jun 2020	31
11	Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy Terence John O'Brien et al. · JAMA Network Open Open access	8 Jul 2022	29
12	Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment Joseph Palumbo, Brian F. Thomas, Dejan B. Budimirovic et al. · Journal of Neurodevelopmental Disorders Open access	9 Jan 2023	26
13	Tibetan Buddhist monastic debate: Psychological and neuroscientific analysis of a reasoning-based analytical meditation practice Marieke K. van Vugt, Amir Moye, Joshua W. Pollock et al. · Progress in brain research Book chapterOpen access	2019	16
14	Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036 Marcel O. Bonn‐Miller, Stan L. Banks, Terri B. Sebree · Cannabis and Cannabinoid Research Open access	2017	13
15	A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)] Elizabeth Berry‐Kravis, Randi Jenssen Hagerman, Dejan B. Budimirovic et al. · Biological Psychiatry	27 Apr 2021	5
16	PRO1 Meaningful Change Thresholds for the Aberrant Behavior Checklist-Community Fragile X Syndrome (ABC-CFXS) in Children and Adolescents with FXS Elizabeth P. Merikle, V. Patel, Timothy Dobbins et al. · Value in Health Open access	Jun 2021	3
17	Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)] Elizabeth P. Merikle, Vanessa Patel, Thomas W Dobbins et al. · Biological Psychiatry	27 Apr 2021	3
18	RECONNECT (ZYN2-CL-033): DESIGN OF A PHASE 3 TRIAL OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME BASED UPON LEARNINGS FROM CONNECT-FX (ZYN2-CL-016) Joseph Palumbo, Nancy Tich, Terri B. Sebree et al. · Journal of the American Academy of Child & Adolescent Psychiatry	Oct 2021	2
19	LONGER-TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030]) Joseph Palumbo, Helen Heussler, Michael Duhig et al. · Journal of the American Academy of Child & Adolescent Psychiatry	Oct 2021	2
20	ST1 Caregiver-Perceived Behavioral Challenges in Fragile X Syndrome (FXS) and Their Measurement Using the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS) Elizabeth P. Merikle, V. Patel, Nancy Tich et al. · Value in Health Open access	Jun 2021	2
21	Quality of Life and Qualitative Caregiver Assessments in Children and Adolescents with Developmental and Epileptic Encephalopathies Treated with Cannabidiol Transdermal Gel: An Open-label Clinical Trial (1664) Lynette Grant Sadleir, Joseph F. Hulihan, John A. Messenheimer et al. · Neurology	14 Apr 2020	1
22	Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open-label Clinical Trial (1631) Ingrid Eileen Scheffer, Joseph F. Hulihan, John A. Messenheimer et al. · Neurology	14 Apr 2020	1
23	Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Behavioral Symptoms in Children and Adolescents With Fragile X Syndrome (ZYN2-CL-017) Nancy Tich, Anthony Thibodeau, Terri B. Sebree et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access	Oct 2023	0
24	Cannabidiol Transdermal Gel for the Treatment of Fragile X Syndrome: Post hoc Responder Analysis and Pattern of Efficacy on domains of the Aberrant Behavior Checklist-FXS (ABC-CFXS) (4743) Joseph Palumbo, Wei Dong Du, Helen Heussler et al. · Neurology	14 Apr 2020	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.